NEW YORK — OncoHelix will market Nanostics' ClarityDx Prostate cancer risk assessment tool in the Middle East, the Canadian companies said on Thursday.
Under the terms of the deal, OncoHelix will offer the test to healthcare providers and their patients in the Middle East through a lab in Abu Dhabi it operates in partnership with United Arab Emirates-based healthcare group Burjeel Holdings.
Additional terms were not disclosed.
ClarityDx Prostate analyzes two blood-based biomarkers — total prostate-specific antigen (PSA) and free PSA — and up to five clinical features including patient age, previous negative biopsy status, digital rectal exam findings, prostate volume, and prostate imaging reporting and data system score. With these data, the tool generates a risk score for prostate cancer aggressiveness.
The test was developed by researchers at Canada's Alberta Prostate Cancer Research Initiative, who formed Nanostics in 2017 to commercialize ClarityDx Prostate and its underlying technology.
Earlier this week, Nanostics announced that it had forged a US marketing pact for ClarityDx Prostate with Protean BioDiagnostics.